RU2018145776A - Комбинированные терапии модуляторами фарензоидного х-рецептора (fxr) - Google Patents

Комбинированные терапии модуляторами фарензоидного х-рецептора (fxr) Download PDF

Info

Publication number
RU2018145776A
RU2018145776A RU2018145776A RU2018145776A RU2018145776A RU 2018145776 A RU2018145776 A RU 2018145776A RU 2018145776 A RU2018145776 A RU 2018145776A RU 2018145776 A RU2018145776 A RU 2018145776A RU 2018145776 A RU2018145776 A RU 2018145776A
Authority
RU
Russia
Prior art keywords
optionally substituted
heteroaryl
alkylene
aryl
group
Prior art date
Application number
RU2018145776A
Other languages
English (en)
Russian (ru)
Other versions
RU2018145776A3 (cg-RX-API-DMAC10.html
Inventor
Раджу Мохан
Бенджамин Энтони ПРАТТ
Original Assignee
Акарна Терапьютикс, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Акарна Терапьютикс, Лтд. filed Critical Акарна Терапьютикс, Лтд.
Publication of RU2018145776A publication Critical patent/RU2018145776A/ru
Publication of RU2018145776A3 publication Critical patent/RU2018145776A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2018145776A 2016-05-25 2017-05-25 Комбинированные терапии модуляторами фарензоидного х-рецептора (fxr) RU2018145776A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662341487P 2016-05-25 2016-05-25
US201662341482P 2016-05-25 2016-05-25
US62/341,482 2016-05-25
US62/341,487 2016-05-25
PCT/US2017/034564 WO2017205684A1 (en) 2016-05-25 2017-05-25 Combination therapies with farnesoid x receptor (fxr) modulators

Publications (2)

Publication Number Publication Date
RU2018145776A true RU2018145776A (ru) 2020-06-26
RU2018145776A3 RU2018145776A3 (cg-RX-API-DMAC10.html) 2021-03-01

Family

ID=60412964

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018145776A RU2018145776A (ru) 2016-05-25 2017-05-25 Комбинированные терапии модуляторами фарензоидного х-рецептора (fxr)

Country Status (13)

Country Link
US (1) US20200397798A1 (cg-RX-API-DMAC10.html)
EP (1) EP3463373A4 (cg-RX-API-DMAC10.html)
JP (1) JP2019517478A (cg-RX-API-DMAC10.html)
KR (1) KR20190040936A (cg-RX-API-DMAC10.html)
CN (1) CN109843298A (cg-RX-API-DMAC10.html)
AU (1) AU2017270221A1 (cg-RX-API-DMAC10.html)
BR (1) BR112018073460A2 (cg-RX-API-DMAC10.html)
CA (1) CA3025007A1 (cg-RX-API-DMAC10.html)
IL (1) IL263179A (cg-RX-API-DMAC10.html)
MX (1) MX2018014024A (cg-RX-API-DMAC10.html)
RU (1) RU2018145776A (cg-RX-API-DMAC10.html)
SG (2) SG11201810290WA (cg-RX-API-DMAC10.html)
WO (1) WO2017205684A1 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019025228A2 (pt) * 2017-06-02 2020-06-23 Akarna Therapeutics, Ltd. Compostos bicíclicos fundidos
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
JP2022514731A (ja) * 2018-08-14 2022-02-15 アヴォリント 原発性硬化性胆管炎の処置方法
WO2020081766A1 (en) * 2018-10-18 2020-04-23 Avolynt Use of sglt2 inhibitors to treat primary sclerosing cholangitis
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN111825653A (zh) * 2019-04-19 2020-10-27 安道麦马克西姆有限公司 取代吡唑类化合物的制备及其作为邻氨基苯甲酰胺前体的用途
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
EP4061357A4 (en) * 2019-11-22 2024-01-10 Avolynt Use of sglt2 inhibitors to treat primary billiary cholangitis
IL296100A (en) * 2020-03-11 2022-11-01 Dong A St Co Ltd A medicinal preparation for the prevention or treatment of non-alcoholic steatohepatitis
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
US20220034871A1 (en) * 2020-07-31 2022-02-03 Daiichi Sankyo Company, Limited Methods for administering pexidartinib
PE20231096A1 (es) 2020-08-25 2023-07-18 Lilly Co Eli Polimorfos de un inhibidor de ssao
US20240319210A1 (en) * 2020-12-18 2024-09-26 Human Metabolomics Institute, Inc. Application of neonatal biliary atresia biomarker and detection method for same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009387A2 (en) * 2003-07-23 2005-02-03 X-Ceptor Therapeutics Inc. Azepine derivatives as pharmaceutical agents
ATE526318T1 (de) * 2005-12-19 2011-10-15 Glaxosmithkline Llc Farnesoid-x-rezeptor-agonisten
EP4137137A1 (en) * 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
AU2015314830B2 (en) * 2014-09-12 2021-01-07 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
CA2968434A1 (en) * 2014-11-21 2016-05-26 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
RU2021107054A (ru) * 2015-03-26 2021-03-31 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания

Also Published As

Publication number Publication date
MX2018014024A (es) 2019-08-29
BR112018073460A2 (pt) 2019-07-09
AU2017270221A1 (en) 2018-12-20
EP3463373A4 (en) 2020-04-22
WO2017205684A1 (en) 2017-11-30
CN109843298A (zh) 2019-06-04
SG10202011660RA (en) 2020-12-30
JP2019517478A (ja) 2019-06-24
KR20190040936A (ko) 2019-04-19
EP3463373A1 (en) 2019-04-10
RU2018145776A3 (cg-RX-API-DMAC10.html) 2021-03-01
CA3025007A1 (en) 2017-11-30
US20200397798A1 (en) 2020-12-24
IL263179A (en) 2018-12-31
SG11201810290WA (en) 2018-12-28

Similar Documents

Publication Publication Date Title
JP2019517478A5 (cg-RX-API-DMAC10.html)
KR102904955B1 (ko) Glp-1r 작용제 및 그의 용도
US12479853B2 (en) HIV inhibitor compounds
TW202317536A (zh) 用於靶向pd-l1之方法及組成物
JP2021518413A5 (cg-RX-API-DMAC10.html)
JP6636539B2 (ja) 変形性関節症の治療のためのadamts阻害剤としての5−[(ピペラジン−1−イル)−3−オキソ−プロピル]−イミダゾリジン−2,4−ジオン誘導体
ES2674531T3 (es) Moduladores del receptor acoplado a la proteína g 40 (gpr40) de pirrolidina para el tratamiento de enfermedades como la diabetes
JP6858984B2 (ja) がんおよび糖尿病の治療に有用な6−ヘテロシクリル−4−モルホリン−4−イルピリジン−2−オン化合物
IL275002B2 (en) Fatty acid derivatives for treating non-alcoholic steatohepatitis
JP2020536911A (ja) Hivプロテアーゼ阻害剤としての1−ベンジル−2−イミノ−4−フェニル−5−オキソイミダゾリジン誘導体
RU2016122908A (ru) Соединения дигидропиримидина и их применение в фармацевтических препаратах
HRP20221437T1 (hr) Agonisti receptora glp-1 i njihova upotreba
RU2010119645A (ru) Замещенные гетероциклом пиперазинодигидротиенопиримидины
RU2014111055A (ru) 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение
CN107406416A (zh) 新型取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途
HRP20110458T1 (hr) Inhibitori rna-ovisne rna-polimeraze iz virusa hepatitisa c, te pripravci i liječenje u kojem se koriste
AU2015239021A1 (en) Substituted fused heterocycles as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
TW202328139A (zh) 用於靶向pd-l1之方法及組成物
JP2019507770A (ja) 2−アミノ−N−[7−メトキシ−2,3−ジヒドロイミダゾ−[1,2−c]キナゾリン−5−イル]ピリミジン−5−カルボキサミド類
JP2019507185A5 (cg-RX-API-DMAC10.html)
WO2021252555A1 (en) Collagen 1 translation inhibitors and methods of use thereof
JP2022509206A5 (cg-RX-API-DMAC10.html)
US20220340561A1 (en) Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
JP2017538711A5 (cg-RX-API-DMAC10.html)
JP2018522927A (ja) ヒト免疫不全ウイルス複製の阻害剤としての5−(n−ベンジルテトラヒドロイソキノリン−6−イル)ピリジン−3−イル酢酸誘導体

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20210820